Automating the prior authorization (PA) process for Repatha®

CoverMyMeds® electronically connects providers, pharmacists, and health plans

- Offers an automated process for submitting electronic PA requests
- Live chat and phone support available
- Available to prescribers and their staff at no charge
- The ability to attach documentation if required

Today, nearly 100 percent of pharmacies, payers and EHRs have adopted an ePA solution[1]

Performance data for CoverMyMeds®:[2]

74% approval rate
for ePAs submitted by HCPs for Repatha®*

48 hour turnaround
for 91% of Repatha® ePAs*

*Based on CoverMyMeds® data from January 2021 ePA trends.

INDICATION

Repatha® is indicated:

- In adults with established cardiovascular disease to reduce the risk of myocardial infarction, stroke, and coronary revascularization

IMPORTANT SAFETY INFORMATION

- **Contraindication:** Repatha® is contraindicated in patients with a history of a serious hypersensitivity reaction to evolocumab or any of the excipients in Repatha®. Serious hypersensitivity reactions including angioedema have occurred in patients treated with Repatha®.

Please see additional Important Safety Information on the last page.

Repatha® (evolocumab) injection 140 mg/mL

Starting a PA request through CoverMyMeds®

Selecting the medication

- When prescribing Repatha®, a drop-down list will appear to select the administration method
- Please note Repatha® SureClick® is the first option on the drop-down
- Be sure to review the administration choice before submitting the PA request



Selecting the correct PA form

- Choose the Patient Insurance State in the drop-down list. Then type in Plan or PBM Name
- If multiple forms appear, select the correct form or use the More Information link. Additional forms may also be available by opening the Show More Forms tab*
- **For best results, select the drug insurance ID card and enter the insurance BIN number**
  - Sometimes located on front or back of the patient's insurance card
  - Patients may have a separate pharmacy benefit card
  - Call the patient's pharmacy where they normally pick up their prescriptions for this information





* There may be lower cost medications available or preferred on your patient's plan. Check patient's specific plan formulary. If prescriber deems alternative medication appropriate, contact pharmacy with new script.

Attaching documentation

- CoverMyMeds® only allows one document to be attached to the form
- If a plan requires additional documentation, all supporting documents **MUST** be combined into a single document no larger than 5 MB
- Alternately, additional documentation may be faxed to CoverMyMeds®
  - Save the PA, then use the chat feature to notify CoverMyMeds® that additional documentation will be faxed
  - Provide Key for PA and number of pages to be faxed
  - Write Key and number of pages on the top of the first page (cover sheet is not required) and fax to 888-965-1415
  - Verify documents are attached by refreshing browser and clicking print/download on the left side of the screen to see all documents
  - Click Send to Plan button
  - CoverMyMeds® typically responds within the chat feature within 1 hour



Send Repatha® prescription to the pharmacy

- You can select any pharmacy that best fits your practice preferences and your Repatha® patient needs; however, some payers may mandate a specific pharmacy for Repatha®

Repatha® (evolocumab) injection 140 mg/mL

INDICATIONS (continued)

Repatha® is indicated:

- As an adjunct to diet, alone or in combination with other low-density lipoprotein cholesterol (LDL-C)-lowering therapies, in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH) to reduce LDL-C
- As an adjunct to other LDL-C-lowering therapies in patients with homozygous familial hypercholesterolemia (HoFH), to reduce LDL-C

  The safety and effectiveness of Repatha® have not been established in pediatric patients with HoFH who are younger than 13 years old or in pediatric patients with primary hyperlipidemia.

IMPORTANT SAFETY INFORMATION

- **Contraindication:** Repatha® is contraindicated in patients with a history of a serious hypersensitivity reaction to evolocumab or any of the excipients in Repatha®. Serious hypersensitivity reactions including angioedema have occurred in patients treated with Repatha®.
- **Hypersensitivity Reactions:** Hypersensitivity reactions, including angioedema, have been reported in patients treated with Repatha®. If signs or symptoms of serious hypersensitivity reactions occur, discontinue treatment with Repatha®, treat according to the standard of care, and monitor until signs and symptoms resolve.
- **Adverse Reactions in Primary Hyperlipidemia:** The most common adverse reactions (>5% of patients treated with Repatha® and more frequently than placebo) were: nasopharyngitis, upper respiratory tract infection, influenza, back pain, and injection site reactions.

  From a pool of the 52-week trial and seven 12-week trials: Local injection site reactions occurred in 3.2% and 3.0% of Repatha®-treated and placebo-treated patients, respectively. The most common injection site reactions were erythema, pain, and bruising. Hypersensitivity reactions occurred in 5.1% and 4.7% of Repatha®-treated and placebo-treated patients, respectively. The most common hypersensitivity reactions were rash (1.0% versus 0.5% for Repatha® and placebo, respectively), eczema (0.4% versus 0.2%), erythema (0.4% versus 0.2%), and urticaria (0.4% versus 0.1%).
- **Adverse Reactions in the Cardiovascular Outcomes Trial:** The most common adverse reactions (>5% of patients treated with Repatha® and more frequently than placebo) were: diabetes mellitus (8.8% Repatha®, 8.2% placebo), nasopharyngitis (7.8% Repatha®, 7.4% placebo), and upper respiratory tract infection (5.1% Repatha®, 4.8% placebo).

  Among the 16,676 patients without diabetes mellitus at baseline, the incidence of new-onset diabetes mellitus during the trial was 8.1% in patients treated with Repatha® compared with 7.7% in patients that received placebo.
- **Adverse Reactions in HoFH:** In a 12-week study in 49 patients, the adverse reactions that occurred in at least two patients treated with Repatha® and more frequently than placebo were: upper respiratory tract infection, influenza, gastroenteritis, and nasopharyngitis. In an open-label extension study in 106 patients, including 14 pediatric patients, no new adverse reactions were observed.
- **Immunogenicity:** Repatha® is a human monoclonal antibody. As with all therapeutic proteins, there is potential for immunogenicity with Repatha®.

Please see full Prescribing Information.

Register online at **covermymeds.com** or call **1-866-452-5017** for support.

References: 1. CoverMyMeds.com. https://www.covermymeds.com/main/medication-access-report/electronic-prior-authorization. Accessed April 14, 2021. **2.** Data on file, Amgen; 2021.

AMGEN®
Amgen
One Amgen Center Drive
Thousand Oaks, CA 91320-1799
www.amgen.com

Repatha® (evolocumab) injection 140 mg/mL